Drug Trial Radar · NCT05501886
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
Last checked: Nov 19, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
701
Planned (sponsor's estimate)
Start
Dec 8, 2022
Primary completion
Jun 30, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Celcuity IncIndustry
- Sponsor type
- Industry
- First posted
- Aug 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.
Conditions
- Breast Cancer
Interventions
GedatolisibDrug
Gedatolisib 180 mg IV given weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off
PalbociclibDrug
Palbociclib 125 mg PO given daily for 3 weeks (21 days), followed by 1 week off
FulvestrantDrug
Fulvestrant 500 mg IM (2 × 5 mL injections) given every 2 weeks during Cycle 1 (Days 1 and 15), then every 4 weeks beginning with Cycle 2 Day 1
AlpelisibDrug
Alpelisib 300 mg PO (2 × 150 mg tablets) given daily for 4 weeks (28 days)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) in Patients with PIK3CA WT and PIK3CA MT Breast CancerTime frame: Approximately 48 months
Locations
235 sites in 23 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Arizona Oncology (US Oncology/McKesson) - Goodyear
Goodyear, Arizona
St. Bernards Medical Center
Jonesboro, Arkansas
CARTI Cancer Center
Little Rock, Arkansas
Pacific Cancer Medical Center Inc
Anaheim, California
Kaiser Permanente South Bay Medical Center
Harbor City, California
Cancer and Blood Specialty Clinic
Los Alamitos, California
Pacific Cancer Care
Monterey, California
University of California, Irvine Medical Center
Orange, California
Ventura County Hematology Oncology Specialists
Oxnard, California
Redlands Hematology Oncology
Redlands, California
UCLA Hematology/Oncology-Santa Monica
Santa Monica, California
Torrance Memorial Physician Network - Cancer Care
Torrance, California
Kaiser Permanente Medical Center - Vallejo
Vallejo, California
PIH Health Hospital Whittier
Whittier, California
Yale Cancer Center - New Haven
New Haven, Connecticut
South Broward Hospital District d/b/a Memorial Healthcare System
Hollywood, Florida
Cancer Specialists of North Florida - Jacksonville
Jacksonville, Florida
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida
Bond & Steele Clinic, P.A. d/b/a Bond Clinic, P.A.
Winter Haven, Florida
John D. Archbold Memorial Hospital
Thomasville, Georgia
Illinois Cancer Specialists - Arlington Heights
Arlington Heights, Illinois
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana
University of Kansas Cancer Center
Westwood, Kansas
University of Kentucky Medical Center
Lexington, Kentucky
Mercy Health - Paducah
Paducah, Kentucky
American Oncology Partners of Maryland, PA
Bethesda, Maryland
Maryland Oncology Hematology, P.A. - Rockville
Rockville, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Henry Ford Hospital
Detroit, Michigan
Nebraska Hematology - Oncology, P.C.
Lincoln, Nebraska
Oncology Hematology West PC dba Nebraska Cancer Specialists
Omaha, Nebraska
University of Nebraska Medical Center
Omaha, Nebraska
New York Oncology Hematology, P.C. - Albany
Albany, New York
Queens Hospital Cancer Center
Jamaica, New York
Coleman, Pasmantier & Decter, MDs
New York, New York
Weill Cornell Medicine/New York-Presbyterian Hospital
New York, New York
University of Rochester Medical Center
Rochester, New York
Hematology/Oncology Associates of Central New York
Syracuse, New York
Showing 40 of 235 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.